| Date | Title | Description |
| 25.12.2025 | US Markets Close 2025 on Record Highs, AI Sector Shifts Focus | US markets achieved new record highs in a holiday-shortened session, capping a year of remarkable gains. The S&P 500, Dow, and Nasdaq all surged. Strong economic data, including robust GDP and falling jobless claims, underpinned this mo... |
| 25.12.2025 | Dow, S&P 500 hit record highs as Santa rally begins | NEW YORK: US stocks closed higher on Wednesday (Dec 24), with the Dow Jones Industrial Average and the S&P 500 finishing at record levels as a broad-based rally extended into a holiday-shortened session and raised hopes of a traditional... |
| 24.12.2025 | US stocks drift to more records on a holiday-shortened day of trading | Getting your Trinity Audio player ready...
NEW YORK (AP) — Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day.
The S&P 500 index rose 22.26 points, or 0.3%, to 6,932.05. The Dow Jones Industr... |
| 24.12.2025 | Stocks making the biggest moves premarket: Nike, Dynavax Technologies, UiPath & more | - |
| 24.12.2025 | European markets close mixed; Novo Nordisk shares jump 9%, extending rally after GLP-1 pill approval | LONDON — European markets closed mixed on Wednesday as investors took stock of the volatile year during Christmas Eve’s shortened trading session.
The pan-European Stoxx 600 finished just below the flatline, with major bourses mixed before ... |
| 23.12.2025 | S&P 500 closes at another fresh record in holiday-shortened session: Live updates | The S&P 500 rose to a new all-time high on Wednesday, coasting to another record close.
The broad market index advanced 0.32%, ending the session at 6,932.05. The Dow Jones Industrial Average gained 288.75 points, or 0.60%, and also pos... |
| 24.05.2025 | United Airlines and its flight attendants reach tentative contract agreement, union says | United Airlines and its flight attendants reach tentative contract agreement, union says
By ReutersMay 23, 20259:08 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
United Airlines flight attenda... |
| 10.01.2022 | Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate | EMERYVILLE, Calif., Jan. 10, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today outlined its strategic prio... |
| 28.12.2021 | COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use | EMERYVILLE, Calif., Dec. 28, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Biological E reported that CORBEVAX™, the... |
| 04.11.2021 | Dynavax Reports Third Quarter 2021 Financial Results | EMERYVILLE, Calif., Nov. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the third quarter e... |
| 27.10.2021 | Medigen's MVC-COV1901 Selected for WHO COVID-19 Solidarity Trial Vaccines | TAIPEI, Oct. 27, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corp (MVC) vaccine candidate, MVC-COV1901, has been recommended by an independent vaccine prioritisation advisory group to be included in the World Health Organisation (WHO) So... |
| 21.10.2021 | Dynavax Technologies : Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman | EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Scott Myers to its B... |
| 18.10.2021 | Dynavax Technologies : COVID-19 Vaccine Developed by Valneva Using Dynavax's CpG 1018 Adjuvant Meets Both Co-Primary Endpoints in Phase 3 COV-COMPARE Trial | EMERYVILLE, Calif., Oct. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE reported positive topline res... |
| 04.10.2021 | Dynavax Technologies : and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using 's CpG 1018 Adjuvant | EMERYVILLE, Calif., Oct. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynav... |
| 23.08.2021 | Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant | |
| 23.08.2021 | Dynavax Technologies : Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant | TAIPEI, Taiwan and EMERYVILLE, Calif., Aug. 23, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax... |
| 04.08.2021 | Dynavax Technologies : Announces Second Quarter 2021 Financial Results | EMERYVILLE, Calif., Aug. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter ... |
| 04.08.2021 | Dynavax Announces Second Quarter 2021 Financial Results | |
| 06.07.2021 | Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate | |
| 06.07.2021 | Dynavax Technologies : and Biological E Announce Commercial Supply Agreement of 's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate | EMERYVILLE, Calif. and HYDERABAD, India, July 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and Biological E. Limited (... |
| 30.06.2021 | Dynavax Technologies : Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate | CHENGDU, China, and EMERYVILLE, Calif., June 30, 2021 /PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's mos... |
| 30.06.2021 | Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate | |
| 30.06.2021 | Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate | |
| 30.06.2021 | Dynavax Technologies : Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate | Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)
Pending conditional regulatory approvals, Clover expects to commence product launch of SC... |
| 30.06.2021 | Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate | Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum)
Pending conditional regulatory approvals, Clover expects to commence product launch of SC... |
| 27.05.2021 | Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany | |
| 27.05.2021 | DYNAVAX TECHNOLOGIES CORPORATION
Dynavax Technologies : Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany | EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization ... |
| 11.05.2021 | Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering | |
| 11.05.2021 | DYNAVAX TECHNOLOGIES CORPORATION
Dynavax Technologies : Announces Pricing of $200 Million Convertible Senior Notes Offering | EMERYVILLE, Calif., May 11, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 (the ... |
| 06.05.2021 | DYNAVAX TECHNOLOGIES CORPORATION
Dynavax Technologies : Announces First Quarter 2021 Financial Results | EMERYVILLE, Calif., May 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of... |
| 06.05.2021 | Dynavax Announces First Quarter 2021 Financial Results | |
| 24.03.2021 | Clover Biopharmaceuticals : and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate | Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA across Latin America, Asia, Europe and Africa
Interim analysis of the primary endpoint expected in the middle of 2021
CHENGDU, China and EMERYVILLE, Cali... |
| 24.03.2021 | Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate | |
| 24.03.2021 | Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate | |
| 25.02.2021 | Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results | |
| 23.02.2021 | Dynavax Technologies : China's Clover raises $230 mln, plans vaccines for COVID-19 variants | BEIJING, Feb 23 (Reuters) - China's Clover Biopharmaceuticals, a developer of coronavirus vaccines, has raised $230 million from investors, including Singapore's state investment firm Temasek Holdings, it said on Tuesday, as it develops vac... |
| 23.02.2021 | DYNAVAX TECHNOLOGIES CORPORATION
Dynavax Technologies : China's Clover raises $230 mln, plans vaccines for COVID-19 variants | BEIJING, Feb 23 (Reuters) - China's Clover Biopharmaceuticals, a developer of coronavirus vaccines, has raised $230 million from investors, including Singapore's state investment firm Temasek Holdings, it said on Tuesday, as it develops vac... |
| 19.02.2021 | Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine | |
| 01.02.2021 | Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet | |
| 01.02.2021 | Clover Biopharmaceuticals : Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet | Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 ... |
| 01.02.2021 | Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government | |
| 01.02.2021 | Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate | |
| 01.02.2021 | Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate | Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potenti... |
| 01.02.2021 | Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate | |
| 20.01.2021 | Dynavax Appoints Kelly MacDonald as Chief Financial Officer | |
| 07.01.2021 | Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis | |
| 05.11.2020 | Dynavax Announces Third Quarter 2020 Financial Results | |
| 13.10.2020 | Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October | |
| 03.08.2020 | TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program | Purchase agreement for up to $250 million in milestone payments plus royalties on future net sales |
| 19.06.2020 | DYNAVAX TECHNOLOGIES CORPORATION
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals' COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant | Preclinical results demonstrated the ability of CpG 1018-adjuvanted SCB-2019 to elicit neutralizing antibodies in multiple animal species
Clover expects to enroll 150 healthy adult and elderly participants in the Phase 1 study
Preliminary s... |
| 04.08.2017 | Is the new Dynavax hepatitis vaccine safe? I couldn’t tell — and I was advising the FDA | The Food and Drug Administration recently had a very important question about a new hepatitis vaccine and wanted advice.
Hepatitis B is a serious disease that can damage the liver. A company called Dynavax has developed a new vaccine that s... |
| 24.10.2011 | GSK expands Dynavax partnership, aims for new lupus, arthritis treatments | Dynavax is developing inhibitors of “toll-like receptors,” or TLRs, which are key receptors of the immune system that can trigger strong inflammatory responses. The change to the GSK-Dynavax partnership adds the receptor TLR8 to the agreeme... |
| - | GSK expands Dynavax partnership, aims for new lupus, arthritis treatments | GlaxoSmithKline (NYSE:GSK) has added a new target to its strategic partnership with California biotechnology company Dynavax Technologies (NASDAQ:DVAX) that could yield potential new treatments for autoimmune and inflammatory diseases.
With... |
